Image

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Trial comparing two treatment combos for relapsed multiple myeloma.

Recruiting
18 years and older
All
Phase 3
  • Simplified description (AI rewritten)
  • Technical description (Original)

Multiple myeloma is a type of blood cancer that affects the bone marrow. This study is for people whose myeloma has come back or hasn't responded to previous treatments. The study compares two treatment combinations. One group gets iberdomide, daratumumab, and dexamethasone (IberDd), while the other group gets daratumumab, bortezomib, and dexamethasone (DVd). The goal is to see which combination works better and is safer for patients. Key Points:

  • The study involves two stages and includes about 864 participants overall.
  • Participants receive treatments until the disease worsens or side effects are too severe.
  • Participants must have tried 1-2 prior treatments and show disease progression.
To join, you need to be diagnosed with multiple myeloma, have tried other treatments, and be able to perform daily activities (ECOG score of 0, 1, or 2). You cannot join if you have certain other medical conditions or have received iberdomide before. The study follows strict rules to keep participants safe and collect accurate data.
Print
Study details
    Multiple Myeloma

NCT04975997

Celgene

16 March 2025

Contact a study center
Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

  Other languages supported:

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.